Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 5/2015

01-05-2015 | Research Article

The methylation of a panel of genes differentiates low-grade from high-grade gliomas

Authors: Aleksandra Majchrzak-Celińska, Jarosław Paluszczak, Marlena Szalata, Anna-Maria Barciszewska, Stanisław Nowak, Robert Kleszcz, Adam Sherba, Wanda Baer-Dubowska

Published in: Tumor Biology | Issue 5/2015

Login to get access

Abstract

Epigenetic changes play an important role in the pathogenesis of gliomas and have the potential to become clinically useful biomarkers. The aim of this study was the evaluation of the profile of promoter methylation of 13 genes selected based on their anticipated diagnostic and/or prognostic value. Methylation-specific PCR (MSP) was used to assess the methylation status of MGMT, ERCC1, hMLH1, ATM, CDKN2B (p15INK4B), p14ARF, CDKN2A (p16INK4A), RASSF1A, RUNX3, GATA6, NDRG2, PTEN, and RARβ in a subset of 95 gliomas of different grades. Additionally, the methylation status of MGMT and NDRG2 was analyzed using pyrosequencing (PSQ). The results revealed that the methylation index of individual glioma patients correlates with World Health Organization (WHO) tumor grade and patient’s age. RASSF1A, RUNX3, GATA6, and MGMT were most frequently methylated, whereas the INK4B-ARF-INK4A locus, PTEN, RARβ, and ATM were methylated to a lesser extent. ERCC1, hMLH1, and NDRG2 were unmethylated. RUNX3 methylation correlated with WHO tumor grade and patient’s age. PSQ confirmed significantly higher methylation levels of MGMT and NDRG2 as compared with normal, non-cancerous brain tissue. To conclude, DNA methylation of a whole panel of selected genes can serve as a tool for glioma aggressiveness prediction.
Literature
1.
Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97–109.CrossRefPubMedPubMedCentral
2.
Cloughesy TF, Cavenee WK, Mischel PS. Glioblastoma: from molecular pathology to targeted treatment. Annu Rev Pathol. 2014;9:1–25.CrossRefPubMed
3.
4.
Barciszewska AM, Nowak S, Naskręt-Barciszewska MZ. The degree of global DNA hypomethylation in peripheral blood correlates with that in matched tumor tissues in several neoplasia. PLoS One. 2014;9(3):e92599.CrossRefPubMedPubMedCentral
5.
Majchrzak-Celińska A, Paluszczak J, Kleszcz R, Magiera M, Barciszewska AM, et al. Detection of MGMT, RASSF1A, p15INK4B, and p14ARF promoter methylation in circulating tumor-derived DNA of central nervous system cancer patients. J Appl Genet. 2013;54(3):335–44.CrossRefPubMedPubMedCentral
6.
Li M, Li J, Liu L, Li W, Yang Y, Yuan J. MicroRNA in human glioma. Cancers (Basel). 2013;5(4):1306–31.CrossRef
7.
8.
Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000;343(19):1350–4.CrossRefPubMed
9.
Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997–1003.CrossRefPubMed
10.
Hegi ME, Liu L, Herman JG, Stupp R, Wick W, et al. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol. 2008;26(25):4189–99.CrossRefPubMed
11.
Cankovic M, Nikiforova MN, Snuderl M, Adesina AM, Lindeman N, et al. The role of MGMT testing in clinical practice: a report of the association for molecular pathology. J Mol Diagn. 2013;15(5):539–55.CrossRefPubMed
12.
Liu ZG, Chen HY, Cheng JJ, Chen ZP, Li XN, et al. Relationship between methylation status of ERCC1 promoter and radiosensitivity in glioma cell lines. Cell Biol Int. 2009;33(10):1111–7.CrossRefPubMed
13.
Chen HY, Shao CJ, Chen FR, Kwan AL, Chen ZP. Role of ERCC1 promoter hypermethylation in drug resistance to cisplatin in human gliomas. Int J Cancer. 2010;126(8):1944–54.PubMed
14.
Gömöri E, Pál J, Mészáros I, Dóczi T, Matolcsy A. Epigenetic inactivation of the hMLH1 gene in progression of gliomas. Diagn Mol Pathol. 2007;16(2):104–7.CrossRefPubMed
15.
Roy K, Wang L, Makrigiorgos GM, Price BD. Methylation of the ATM promoter in glioma cells alters ionizing radiation sensitivity. Biochem Biophys Res Commun. 2006;344(3):821–6.CrossRefPubMed
16.
He J, Qiao JB, Zhu H. p14ARF promoter region methylation as a marker for gliomas diagnosis. Med Oncol. 2011;28(4):1218–24.CrossRefPubMed
17.
Wakabayashi T, Natsume A, Hatano H, Fujii M, Shimato S, et al. p16 promoter methylation in the serum as a basis for the molecular diagnosis of gliomas. Neurosurgery. 2009;64(3):455–61.CrossRefPubMed
18.
Avci CB, Dodurga Y, Susluer SY, Sýgva ZO, Yucebas M, et al. Promoter hypermethylation-mediated down-regulation of RUNX3 gene in human brain tumors. Ir J Med Sci. 2013;PMID: 23934435.
19.
Mueller W, Nutt CL, Ehrich M, Riemenschneider MJ, von Deimling A, et al. Downregulation of RUNX3 and TES by hypermethylation in glioblastoma. Oncogene. 2007;26(4):583–93.CrossRefPubMed
20.
Tepel M, Roerig P, Wolter M, Gutmann DH, Perry A, et al. Frequent promoter hypermethylation and transcriptional downregulation of the NDRG2 gene at 14q11.2 in primary glioblastoma. Int J Cancer. 2008;123(9):2080–6.CrossRefPubMed
21.
Skiriute D, Vaitkiene P, Saferis V, Asmoniene V, Skauminas K, et al. MGMT, GATA6, CD81, DR4, and CASP8 gene promoter methylation in glioblastoma. BMC Cancer. 2012;12:218.CrossRefPubMedPubMedCentral
22.
Piperi C, Themistocleous MS, Papavassiliou GA, Farmaki E, Levidou G, et al. High incidence of MGMT and RARbeta promoter methylation in primary glioblastomas: association with histopathological characteristics, inflammatory mediators and clinical outcome. Mol Med. 2010;16(1–2):1–9.CrossRefPubMed
23.
Mueller S, Phillips J, Onar-Thomas A, Romero E, Zheng S, et al. PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome. Neuro Oncol. 2012;14(9):1146–52.CrossRefPubMedPubMedCentral
24.
Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996;93(18):9821–6.CrossRefPubMedPubMedCentral
25.
Håvik AB, Brandal P, Honne H, Dahlback HS, Scheie D, et al. MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR. J Transl Med. 2012;10:36.CrossRefPubMedPubMedCentral
26.
Chen PC, Tsai MH, Yip SK, Jou YC, Ng CF, et al. Distinct DNA methylation epigenotypes in bladder cancer from different Chinese sub-populations and its implication in cancer detection using voided urine. BMC Med Genomics. 2011;4:45.CrossRefPubMedPubMedCentral
27.
Cencioni C, Spallotta F, Martelli F, Valente S, Mai A, et al. Oxidative stress and epigenetic regulation in ageing and age-related diseases. Int J Mol Sci. 2013;14(9):17643–63.CrossRefPubMedPubMedCentral
28.
Kuo LT, Tsai SY, Chang CC, Kuo KT, Huang AP, et al. Genetic and epigenetic alterations in primary-progressive paired oligodendroglial tumors. PLoS One. 2013;8:6.
29.
Paluszczak J, Misiak P, Wierzbicka M, Woźniak A, Baer-Dubowska W. Frequent hypermethylation of DAPK, RARbeta, MGMT, RASSF1A and FHIT in laryngeal squamous cell carcinomas and adjacent normal mucosa. Oral Oncol. 2011;47(2):104–7.CrossRefPubMed
30.
Wemmert S, Bettscheider M, Alt S, Ketter R, Kammers K, et al. p15 promoter methylation—a novel prognostic marker in glioblastoma patients. Int J Oncol. 2009;34(6):1743–8.PubMed
31.
Klein O, Grignon Y, Civit T, Auque J, Marchal JC. Methylation status of RARbeta gene promoter in low and high grade cerebral glioma. Comparison with normal tissue. Immuno-histochemical study of nuclear RARbeta expression in low and high grade cerebral glioma cells. Comparison with normal cells. 48 tumors. Neurochirurgie. 2005;51(3–4 Pt 1):147–54.CrossRefPubMed
32.
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96.CrossRefPubMed
33.
van den Bent MJ, Dubbink HJ, Sanson M, van der Lee-Haarloo CR, Hegi M, et al. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. J Clin Oncol. 2009;27(35):5881–6.CrossRefPubMedPubMedCentral
34.
Christians A, Hartmann C, Benner A, Meyer J, von Deimling A, et al. Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma. PLoS One. 2012;7:3.CrossRef
35.
Preusser M, Berghoff AS, Manzl C, Filipits M, Weinhäusel A, et al. Clinical Neuropathology practice news 1–2014: pyrosequencing meets clinical and analytical performance criteria for routine testing of MGMT promoter methylation status in glioblastoma. Clin Neuropathol. 2014;33(1):6–14.CrossRefPubMed
36.
Lusis EA, Watson MA, Chicoine MR, Lyman M, Roerig P, et al. Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma. Cancer Res. 2005;65(16):7121–6.CrossRefPubMed
37.
Li W, Chu D, Chu X, Meng F, Wei D, et al. Decreased expression of NDRG2 is related to poor overall survival in patients with glioma. J Clin Neurosci. 2011;18(11):1534–7.CrossRefPubMed
38.
Piepoli A, Cotugno R, Merla G, Gentile A, Augello B, et al. Promoter methylation correlates with reduced NDRG2 expression in advanced colon tumour. BMC Med Genomics. 2009;2:11.CrossRefPubMedPubMedCentral
Metadata
Title
The methylation of a panel of genes differentiates low-grade from high-grade gliomas
Authors
Aleksandra Majchrzak-Celińska
Jarosław Paluszczak
Marlena Szalata
Anna-Maria Barciszewska
Stanisław Nowak
Robert Kleszcz
Adam Sherba
Wanda Baer-Dubowska
Publication date
01-05-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 5/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-3025-3

Other articles of this Issue 5/2015

Tumor Biology 5/2015 Go to the issue

Research Article

The circadian gene CRY2 is associated with breast cancer aggressiveness possibly via epigenomic modifications

Research Article

Role of EHD2 in migration and invasion of human breast cancer cells

Research Article

Comparison of circulating and intratumoral regulatory T cells in patients with renal cell carcinoma

Research Article

XRCC1 genetic polymorphism acts a potential biomarker for lung cancer

Research Article

TP53 mutation analysis in chronic lymphocytic leukemia: comparison of different detection methods

Research Article

Transcriptome profiling of the cancer and adjacent nontumor tissues from cervical squamous cell carcinoma patients by RNA sequencing
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits